Clinical Trial UCI-16-52

Title

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Principal Investigator

Krishnansu Tewari

Details

Learn More

For more information about cancer clinical trials at the Chao Family Comprehensive Cancer Center, please call toll-free: 877.UC.STUDY (877.827.8839) or email ucstudy@uci.edu